FEBS Letters | |
Cannabinoids enhance human B‐cell growth at low nanomolar concentrations | |
Casellas, P.1  Ségui, M.1  Le Fur, G.1  Derocq, J.-M.1  Marchand, J.1  | |
[1] Department of Immunology, Sanofi Recherche, 371 rue du Professeur Blayac, 34184 Montpellier Cedex 04, France | |
关键词: Cannabinoid; Immunomodulation; B-Cell activation; CP55; 940; Δ-Tetrahydrocannabinol; WIN55212-2; | |
DOI : 10.1016/0014-5793(95)00746-V | |
学科分类:生物化学/生物物理 | |
来源: John Wiley & Sons Ltd. | |
【 摘 要 】
This study examined the effect of cannabinoid ligands on human tonsillar B-cells activated either through cross-linking of surface immunoglobulins or ligation of the CD40 antigen. The two synthetic cannabinoids, CP55,940 and WIN55212-2, as well as Δ9-tetrahydrocannabinol (THC), the psychoactive component of marijuana, caused a dose-dependent increase of B-cell proliferation and displayed EC50 at low nanomolar concentrations. This cannabinoid-induced enhancing activity was inhibited by pertussis toxin which suggested a G-protein-coupled receptor process. In addition, the absence of antagonistic effect of SR141716A, a specific CB1 receptor antagonist, together with the demonstration that human B-cells displayed large amount of CB2 receptor mRNAs, led us to assume that the growth enhancing activity observed on B-cells at very low concentrations of cannabinoids could be mediated through the CB2 receptor.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201912020301446ZK.pdf | 536KB | download |